Retatrutide, a novel dual agonist of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) receptor , is exhibiting promising outcomes in initial clinical trials . Ongoing inquiry https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/